Contact Us »
Wake Up To WAKIX
Hero name Tara
In adults with narcolepsy, WAKIX is a once-daily medication approved to treat
the two most common symptoms: EDS and cataplexy1,2

Based on a US retrospective cohort study of insured patients…

The number of people under medical care for narcolepsy begins to peak at 18 to 24 years of age3,*

*This study was conducted to estimate the prevalence of narcolepsy in a US insured population of more than 60 million participants between 2013 and 2016.

    For your patients like TaraWhy WAKIX?

  • Not a controlled substance
  • Not a stimulant
  • No clinically important PK interactions with modafinil or sodium oxybate
  • Strong recommendation for the treatment of narcolepsy in adults in the AASM Clinical Practice Guideline (clinically significant improvement in EDS and cataplexy)4
  • AASM, American Academy of Sleep Medicine; EDS, excessive daytime sleepiness; PK, pharmacokinetic.

    Clinical practice guideline on the treatment of central disorders of hypersomnolence, published in the Journal of Clinical Sleep Medicine.

Review Real WAKIX Patient Cases From Experienced Clinicians

Ben real WAKIX patient caseBen real WAKIX patient case


26-year-old student with narcolepsy type 1

Justine real WAKIX patient caseJustine real WAKIX patient case


22-year-old college student with narcolepsy type 2

Owen real WAKIX patient caseOwen real WAKIX patient case


23-year-old pharmacy student with narcolepsy type 1

Abby real WAKIX patient caseAbby real WAKIX patient case


24-year-old computer programmer with narcolepsy type 1

See more real WAKIX
patient case studies »
Learn more about WAKIX»Get your patients started»


  1. American Academy of Sleep Medicine. International Classification of Sleep Disorders. 3rd ed. Text Revision. American Academy of Sleep Medicine; 2023.
  2. Ahmed I, Thorpy M. Clinical features, diagnosis and treatment of narcolepsy. Clin Chest Med. 2010;31(2):371-381.
  3. Acquavella J, Mehra R, Bron M, Suomi JM, Hess GP. Prevalence of narcolepsy and other sleep disorders and frequency of diagnostic tests from 2013-2016 in insured patients actively seeking care. J Clin Sleep Med. 2020;16(8):1255-1263.
  4. Maski K, Trotti LM, Kotagal S, et al. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2021;17(9):1881-1893.